Delving into the Latest Updates on Eyestem Research Pvt Ltd. with Synapse

Overview

Tags

Eye Diseases

Congenital Disorders

Other Diseases

Cell therapy

Gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Cell therapy	3
Unknown	1
Gene therapy	1

The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
The main questions it aims to answer are:
* Safety and tolerability of the novel stem cell formulation
* Potential efficacy of the novel stem cell formulation
Participants will receive a single subretinal injection in their study eye and followed up for safety.
This is an India only study and the product is developed indigenously.

Start Date04 Jun 2024

Sponsor / Collaborator

Eyestem Research Pvt Ltd.Startup

CTRI/2024/04/065639

/ Not yet recruitingPhase 1/2

A Phase 1/2a Multi-Center Dose-Escalation Dose-Expansion Study toEvaluate the Safety and Efficacy of Eyecyte-RPE™ when administered as aSingle-dose Subretinal Injection in Subjects with Geographic AtrophyGA Secondary to Dry Age-related Macular Degeneration d-AMD - NIL

Start Date13 May 2024

Sponsor / Collaborator

Eyestem Research Pvt Ltd.Startup

100 Clinical Results associated with Eyestem Research Pvt Ltd.

Login to view more data

0 Patents (Medical) associated with Eyestem Research Pvt Ltd.

Login to view more data

1

Literatures (Medical) associated with Eyestem Research Pvt Ltd.

IHOPE Journal of Ophthalmology

Stem cell treatment for dry AMD

Author: Narasimhaiah, Swathi ; Prabhu, Rashmi ; Battu, Rajani

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide, affecting a significant proportion of the aging population. While wet AMD can be treated with anti-vascular endothelial growth factor injections, there is very little that can be offered to patients with dry AMD. This paper provides a review of AMD pathogenesis, current treatment methods for dry AMD, and the potential of cell-based therapies, particularly in the context of retinal pigment epithelium (RPE) replacement. AMD pathogenesis involves the formation of drusen impacting the health of the RPE. Aging, smoking, and genetic factors contribute to RPE dysfunction, leading to the progression of AMD. Newer therapies for dry AMD, including pegcetacoplan and avacincaptad pegol, mainly focus on reducing ongoing inflammation and addressing issues with complement regulation. This review discusses the emerging field of RPE replacement therapies, emphasizing the potential of induced pluripotent stem cells. Clinical trials involving RPE replacement therapy are discussed, showcasing ongoing efforts to develop effective treatments for dry AMD. While challenges, including immune rejection and integration issues, have to be solved, the potential benefits of RPE transplantation, either as cell suspensions or patches, remain significant. In conclusion, this paper highlights the promising prospects and challenges related to stem cell science in treating dry AMD, potentially marking a significant breakthrough in managing a previously untreatable disease.

100 Deals associated with Eyestem Research Pvt Ltd.

Login to view more data

100 Translational Medicine associated with Eyestem Research Pvt Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Eyecyte-RPE	Geographic Atrophy More	Phase 2 Clinical
AAV- mediated gene augmentation platform(Eyestem)	Hereditary retinal dystrophy More	Preclinical
EyeCyte-PRP	Retinal Dystrophies More	Preclinical
AirCyte-AEC	Idiopathic Pulmonary Fibrosis More	Preclinical
Neural Progenitor Cells(Eyestem Research)	Parkinson Disease More	Discovery